These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 498418)

  • 1. Distribution and metabolism of rubidazone and daunorubicin in mice.
    Baurain R; Deprez-De Campeneere D; Trouet A
    Cancer Chemother Pharmacol; 1979; 2(1):37-41. PubMed ID: 498418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of the anthracycline antibiotic daunorubicin to daunorubicinol and deoxydaunorubicinol aglycone in hepatocytes isolated from the rat and the rabbit.
    Gewirtz DA; Yanovich S
    Biochem Pharmacol; 1986 Nov; 35(22):4059-64. PubMed ID: 3778526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute cardiovascular alterations induced by low doses of adriamycin, rubidazone, and daunorubicin in the anesthetized beagle dog.
    Herman EH; Young RS
    Cancer Treat Rep; 1979; 63(11-12):1771-9. PubMed ID: 526912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat.
    Cusack BJ; Young SP; Olson RD
    Cancer Chemother Pharmacol; 1995; 35(3):213-8. PubMed ID: 7805179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
    Jaenke RS; Deprez-DeCampeneere D; Trouet A
    Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 trial and assay of rubidazone (NSC 164011) in patients with advanced solid tumors.
    Kovach JS; Ames MM; Sternad ML; O'Connell MJ
    Cancer Res; 1979 Mar; 39(3):823-8. PubMed ID: 427770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo.
    Skovsgaard T
    Cancer Chemother Rep; 1975; 59(2 Pt 1):301-8. PubMed ID: 1149008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation.
    Maniez-Devos DM; Baurain R; Lesne M; Trouet A
    J Pharmacol; 1986; 17(1):1-13. PubMed ID: 3713196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of daunorubicinol in the rabbit: comparison with daunorubicin.
    Maniez-Devos DM; Baurain R; Trouet A; Lesne M
    J Pharmacol; 1986; 17(1):14-20. PubMed ID: 3713197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological and therapeutic efficacy of rubidazone in mice. Comparison with daunomycin and adriamycin.
    Ohnuma T; Elias F; Holland JF; Henderson E
    Eur J Cancer (1965); 1979 Mar; 15(3):363-71. PubMed ID: 446517
    [No Abstract]   [Full Text] [Related]  

  • 11. Daunorubicin-induced cardiac injury in the rabbit: a role for daunorubicinol?
    Cusack BJ; Mushlin PS; Voulelis LD; Li X; Boucek RJ; Olson RD
    Toxicol Appl Pharmacol; 1993 Feb; 118(2):177-85. PubMed ID: 8441996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daunorubicin metabolites in human urine.
    Takanashi S; Bachur NR
    J Pharmacol Exp Ther; 1975 Oct; 195(1):41-9. PubMed ID: 1181403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatobiliary metabolism and urinary excretion of 4-demethoxydaunorubicin as compared to daunorubicin in rats.
    Catapano CV; Guaitani A; Broggini M; Corada M; Bartosek I; Italia C; Donelli MG
    Anticancer Res; 1988; 8(4):725-31. PubMed ID: 3178163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of daunorubicinol in daunorubicin-induced cardiotoxicity as evaluated with the model of isolated perfused rat heart.
    Platel D; Bonoron-Adèle S; Robert J
    Pharmacol Toxicol; 2001 May; 88(5):250-4. PubMed ID: 11393585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors.
    Formelli F; Casazza AM; Di Marco A; Mariani A; Pollini C
    Cancer Chemother Pharmacol; 1979; 3(4):261-9. PubMed ID: 294954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells.
    Skovsgaard T
    Biochem Pharmacol; 1977 Feb; 26(3):215-22. PubMed ID: 14644
    [No Abstract]   [Full Text] [Related]  

  • 17. Biological activities of rubidazone.
    Maral R
    Cancer Chemother Pharmacol; 1979; 2(1):31-5. PubMed ID: 498417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rubidazone vs adriamycin: an evaluation of their differential toxicity in the spleen colony assay system.
    Alberts DS; Van Daalen Wetters T
    Br J Cancer; 1976 Jul; 34(1):64-8. PubMed ID: 952715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells.
    Skovsgaard T
    Biochem Pharmacol; 1978; 27(8):1221-7. PubMed ID: 567991
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative metabolism of daunorubicin and 4-demethoxydaunorubicin in mice and rabbits.
    Broggini M; Sommacampagna B; Paolini A; Dolfini E; Donelli MG
    Cancer Treat Rep; 1986 Jun; 70(6):697-702. PubMed ID: 3524823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.